MREO
vs
S&P 500
MREO
S&P 500
Over the past 12 months, MREO has underperformed S&P 500, delivering a return of -41% compared to the S&P 500's +14% growth.
Stocks Performance
MREO vs S&P 500
Performance Gap
MREO vs S&P 500
Performance By Year
MREO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Mereo Biopharma Group PLC
Glance View
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm is focused on oncology and rare diseases. The firm is focused on development and commercialization of therapeutic pharmaceutical products. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, Etigilimab (MPH-313) for patients with advanced or metastatic solid tumors; Alvelestat (MPH-966) for the treatment of severe Alpha-1 Antitrypsin Deficiency (AATD) and coronavirus disease; Setrusumab (BPS-804) for the treatment of Osteogenesis Imperfecta (OI); Navicixizumab (OMP-305B83) for the treatment of platinum-resistant ovarian cancer; Acumapimod (BCT-197) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and Leflutrozole (BGS-649) for the treatment of male infertility associated with hypogonadotropic hypogonadism (HH).